


Syngene expands biopharma-manufacturing capacity

12 August 2021 | News

Sets up a state-of-the-art microbial facility; expands mammalian facility



Syngene International has announced the expansion of its biomanufacturing capacity. The company has set up and commissioned a new microbial cGMP facility and has also expanded the capacity of its mammalian cell manufacturing facility to extend end-to-end Chemistry, Manufacturing and Control (CMC) development solutions for its global clients. Both facilities are located at its Biocon Park campus in Bengaluru, India.

The new microbial facility has two fermenters of 200 Litres and 500 Litres capacity. The microbial facility will provide further integration opportunities with the Company's existing Discovery and Development capabilities and extend service offerings in the space of GMP manufacturing of plasmid DNA and mRNA.

In addition to this, another 2000L single use bioreactor will be added to the USFDA and EMA compliant mammalian manufacturing facility. This is expected to strengthen Syngene's service offerings for commercial supply.

Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited said "Use of digitalization and automation tools like electronic quality records and digital signatures will not only help avoid the risk of human errors, but also decrease operational costs and improve time-to-market. Both the facilities are supported by proven processes for efficient, scalable, customized and regulator-compliant commercial manufacturing."